Sandu Pharmaceuticals Ltd — Important, 01-10-2025: Company Update

Sandu Pharmaceuticals' 40th Annual General Meeting members approved several key agenda items. Shareholders ratified the remuneration for M/s. Shekhar Joshi & Co as Cost Auditor. They also appointed M/S Swapnil J Dixit & Associates as Secretarial Auditor for a five-year term. A material related party transaction with M/s Sandu Brothers Private Limited was also approved. Furthermore, members endorsed the continuation of Shri. Vijay Kajarakar as Chief Financial Officer, beyond 70 years of age, based on the Board's input. These approvals secure essential governance, audit functions, and continuity in senior management, which is important for business stability.